Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Abroad (travel likely)RecruitingPHASE1
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Recurrent Secondary Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia · Refractory Secondary Acute Myeloid Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
OHSU Knight Cancer Institute, Portland, Oregon, United States
Contact: Principal Investigator (Jennifer N. Saultz, MD)UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Study leads
Jennifer N. Saultz, MD
Principal Investigator
OHSU Knight Cancer Institute